1,720,992 research outputs found
Hypoadiponectinemia is closely associated with nonalcoholic hepatic steatosis in obese subjects.
No full textRetinopathy predicts future cardiovascular events among type 2 diabetic patients - The Valpolicella Heart Diabetes Study.
No full textRetinopathy predicts cardiovascular mortality in type 2 diabetic men and women: response to Juutilainen et al.
No full textNo abstract available
The International Diabetes Federation definition of the metabolic syndrome independently predicts future cardiovascular events among type 2 diabetic patients - The Valpolicella Heart Diabetes Study.
No full text
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Measurement of microvolt T-wave alternans, a new arrhythmic risk stratification test, in type 2 diabetic patients without clinical cardiovascular disease.
No full textNonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.
No full textNonalcoholic fatty liver disease (NAFLD) is closely correlated
to several metabolic syndrome features. We assessed prospectively whether NAFLD predicts future cardiovascular
disease (CVD) events among type 2 diabetic individuals, independent of metabolic syndrome features and other classical risk factors. We carried out a prospective nested case-control study in 2,103 type 2 diabetic patients who were free of diagnosed CVD at baseline. During 5 years of follow-up, 248 participants (case subjects) subsequently developed nonfatal coronary heart disease (myocardial infarction and coronary revascularization procedures), ischemic stroke, or cardiovascular death. Using risk-set sampling, 496 patients (control subjects) among those who remained free of diagnosed CVD during follow-up were randomly selected in a 2:1 ratio, matched for age and sex to the case subjects. After adjustment for age, sex, smoking history, diabetes duration, HbA1c, LDL cholesterol, liver
enzymes, and use of medications, the presence of NAFLD was significantly associated with an increased CVD risk (odds ratio 1.84, 95% CI 1.4 –2.1, P < 0.001). Additional adjustment for the metabolic syndrome (as defined by National Cholesterol Education Program Adult Treatment Panel III criteria) appreciably attenuated, but did not abolish, this association (1.53, 1.1–1.7, P = 0.02). In conclusion, NAFLD is significantly associated with a moderately increased CVD risk among type 2 diabetic individuals. This relationship is independent of classical risk factors and is only partly explained by occurrence of metabolic syndrome
Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients
No full text- …
